Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | KDM6B | O15054 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.42 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.42 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30849093 | 0.83 | TDP1 (0.46) | KDM4CL3MBTL1KDM4EALDH1A1TDP1 | |
| SCHEMBL16414200 | 0.83 | TDP1 (0.46) | KDM4CL3MBTL1KDM4EALDH1A1TDP1 | |
| SCHEMBL29578794 | 0.81 | KDM4C (0.59) | KDM4CL3MBTL1KDM4EALDH1A1TDP1 | |
| SCHEMBL82604 | 0.81 | KDM4C (0.59) | KDM4CL3MBTL1KDM4EALDH1A1TDP1 | |
| SCHEMBL28317597 | 0.80 | TDP1 (0.50) | KDM4CL3MBTL1KDM4EALDH1A1TDP1 | |
| SCHEMBL25201864 | 0.79 | KDM4C (0.42) | LOXL2KDM4CL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL2618803 | 0.79 | TDP1 (0.55) | LOXL2KDM4CL3MBTL1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1027857 | 0.79 | KDM4C (0.57) | KDM4CL3MBTL1KDM4EALDH1A1TDP1 | |
| SCHEMBL19273667 | 0.79 | LOXL2 (0.39) | LOXL2KDM4CL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL724581 | 0.79 | ALDH1A1 (0.52) | LOXL2KDM4CL3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111244543-A | High-voltage lithium ion battery electrolyte additive, electrolyte, battery and formation method thereof | 松山湖材料实验室 | 2020-06-05 | — | — | CN | claimed |
| EP-4743455-A1 | SARM1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025012296-A1 | SARM1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-16 | — | — | WO | disclosed |
| CN-118255747-A | 3-Trifluoromethyl substituted pyrazole compound or pharmaceutically acceptable salt thereof and application thereof | 中山大学 | 2024-06-28 | — | — | CN | disclosed |
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| CN-116981667-A | Heterocyclic inhibitors of EGFR and/or HER2 for cancer treatment | 蝎子疗法股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-4225445-A2 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3440078-B1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD (IN) | 2022-09-28 | — | — | EP | disclosed |
| WO-2022076831-A2 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076831-A2 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2007068728-A2 | N-SUBSTITUTED PYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007068728-A2 | N-SUBSTITUTED PYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| EP-1720855-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1660085-A1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005085227-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
| WO-2005013986-A1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | MAP3K6, MAP3K5, MAP4K2 | LOXL2 1779/4885KDM4C 1128/4885L3MBTL1 2194/4885 |
| US-20240101576-A1 | HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | LOXL2 1519/4885KDM4C 4306/4885L3MBTL1 4388/4885 |
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | CDK2, MAP3K19, MAP3K7 | LOXL2 4115/4885KDM4C 893/4885L3MBTL1 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.